Blockchain Registration Transaction Record

Diabetes Patients Fare Better with Prasugrel Than Ticagrelor After Stent

New study finds prasugrel outperforms ticagrelor in diabetic patients after stent placement, reducing heart attack, stroke, bleeding & death risks. Research challenges interchangeable use.

This research matters because it challenges current medical practice where two commonly prescribed blood-thinning medications are often used interchangeably in diabetic patients receiving stents. For the millions of people worldwide with diabetes who undergo coronary stent procedures, the choice between prasugrel and ticagrelor could significantly impact their risk of serious complications including heart attack, stroke, bleeding events, and even death. Diabetes patients already face elevated cardiovascular risks, and this study suggests that selecting the more effective antiplatelet medication could meaningfully improve their outcomes and quality of life following stent placement. The findings emphasize the importance of personalized medicine in cardiovascular care and may influence future treatment guidelines for this vulnerable patient population.